Diagnostic Company LumiraDX Goes Public In $5Bn SPAC Merger
LumiraDX secured $400m in new debt financing and will use all proceeds to fund growth.
You may also be interested in...
The SPAC deal between CM Life Sciences II and SomaLogic is valued at $1.25bn.
As the SPAC boom continues, innovative medtechs are expected to become acquisition targets.
Smith + Nephew is expanding its suite of simulation technologies to train surgeons on new techniques before they enter the operating room.